THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Rajagopal Ramesh to Xenograft Model Antitumor Assays

This is a "connection" page, showing publications Rajagopal Ramesh has written about Xenograft Model Antitumor Assays.
  1. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther. 2007 Feb; 15(2):287-94.
    View in: PubMed
    Score: 0.255
  2. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017 08; 16(8):1470-1486.
    View in: PubMed
    Score: 0.130
  3. EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. Int J Nanomedicine. 2014; 9:3825-39.
    View in: PubMed
    Score: 0.107
  4. Nanoparticle-mediated gene delivery to the lung. Methods Mol Biol. 2008; 433:301-31.
    View in: PubMed
    Score: 0.068
  5. MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo. Mol Cancer. 2007 Feb 02; 6:11.
    View in: PubMed
    Score: 0.064
  6. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation. Mol Ther. 2004 Jun; 9(6):818-28.
    View in: PubMed
    Score: 0.013
  7. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2002 Sep; 8(9):2963-9.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES